The National Medical Task Force for Combating the Coronavirus (COVID-19)
Vaccination of children aged 3-11 suffering from comorbidities and low immunity with the Sinopharm vaccine
The Taskforce announced the Vaccination Committee’s approval of the vaccination of children aged 3-11 suffering from comorbidities and low immunity with the Sinopharm vaccine.
The decision was taken to safeguard public health, and is based on a study that reviewed COVID-19 symptoms in patients suffering from diseases that cause weak immunity, including; respiratory illnesses, heart disease, diabetes, cancer, down syndrome, birth defects and obesity.
The Taskforce further noted the Vaccination Committee’s approval of the Sinopharm vaccine for those aged 12 to 17 years, in addition to the Pfizer-BioNTech vaccine.
An approval from a guardian is needed, in addition to the presence of a guardian when taking the vaccine.